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PCR using allele-specific probes, and CYP2C9*3 by PCR-RFLP. PHT 
plasma levels were determined by radioimmunoassay.
Results: Twenty-six patients showed PHT therapeutic levels (10–20 
µg/mL), 24 subtherapeutic and 7 supratherapeutic. Three cases, 
2 CYP2C9 *1/*2, and 1 CYP2C19*1/3, had subtherapeutic levels. 
Patients with wild-type ABCB1 and ABCC2 genotypes exhibited a 
tendency to have increased PHT plasma levels than patients with 
mutant genotypes.
Conclusion: PHT plasma levels showed great variability among 
patients that was not statistically significant correlated to the genetic 
polymorphisms analyzed, although ABCB1 and ABCC2 wild-type 
genotypes showed a trend toward higher levels. Further investigations 
are needed with other candidate genes and a larger sample.
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Introduction: Aspirin is an antiplatelet agent commonly used in 
treatment of patients with high risk to develop stroke and myocar-
dial infarction. However, interindividual variability regarding the 
inhibition of platelet function by aspirin is well documented. In this 
study, the correlation between platelet glycoproteins (GPIa C807T 
and GPIba C-5T) and cyclooxygenase 2 (COX-2 G-765C) poly-
morphisms and antiplatelet response in patients treated with aspirin 
was investigated.
Patients (or Materials) and Methods: Jordanian adult patients 
(n = 584) who are taking aspirin as an antiplatelet agent partici-
pated in the study. Platelet aggregation response was measured using 
Multiplate Analyzer® system. Polymerase chain reaction–restriction 
fragment length polymorphism assay (PCR-RFLP) was used for geno-
typing of the examined polymorphisms.
Results: Aspirin resistance was found in 15.8% of patients. Response 
to aspirin was significantly associated with GPIba C-5T polymor-
phism (P < 0.05). However, the GPIa C807T and COX-2 G-765C 
polymorphisms were not related to aspirin resistance (P > 0.05).
Conclusion: A considerable fraction of the Jordanian population is 
resistant to the antiplatelet effect of aspirin, which might be related 
to GPIba C-5T polymorphism.
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Introduction: Pharmacogenomics is intervening in cardiovascular 
therapeutic armamentarium to tailor therapy to individual’s genetic 
makeup. Accordingly, the potential implication of PlA gene variants 
of GPIIIa of platelet GP IIb/IIIa as a genetic risk factor provocateur 
and/or a therapeutic outcome modulator to antiplatelet therapy in 
ACS was probed.
Patients (or Materials) and Methods: Study enrolled 22 controls 
and 44 ACS patients (NSTEMI vs STEMI). They were risk strati-
fied (TIMI score), sampled for genotyping and estimation of plate-
let aggregation and oxidative indices, then subdivided according to 
add-on antiplatelet therapy into: clopidogrel or tirofiban subgroups. 
After 48 hours, the therapeutic outcome was assessed; clinically [pain 
relief or complication prevalence (symptomatic, electrocardiographic, 
or hemorrhagic) and the investigational estimates were re-assessed. 
Intraprocedural evaluation of chest pain, ECG tracing, and angio-
graphic findings (thrombus extent, TIMI flow, myocardial blush) 
were reported in patients who underwent percutaneous intervention 
[PCI].
Results: Frequency of PlA2 vs PlA1 allele was higher in ACS patients 
(significant in < 60 years /doubled in STEMI vs NSTEMI). TIMI 
score, stratification permitted considering PlA2 variant as inde-
pendent risk factor in UA/NSTEMI subsets. This was fostered by 
intraprocedural finding of more stenotic and thrombotic lesions in 
PlA2 carriers. A lack of significant association between PlA variants 
and changes in platelet aggregation or oxidative indices, debate their 
causal relation to PlA2 variant being an ACS risk factor. A positive 
correlation was observed between PlA variants and the therapeutic 
response outcome to both clopidogrel and tirofiban regarding platelet 
aggregation and relief of chest pain while their antioxidative poten-
tiality was negatively correlated only to PlA1 carriers.
Conclusion: PlA2 variant could be considered a genetic risk factor 
contributor rather than an antiplatelet therapeutic response modula-
tor when speaking of ACS. This awaits larger scale pharmacogenomic 
studies before a final statement is declared so as to individualize anti-
platelet therapy to the best of its therapeutic outcome in ACS settings.
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Introduction: Ultrarapid drug metabolism (UM) mediated by 
CYP2D6 is associated with duplicated or amplified functional 
CYP2D6 alleles. However, duplicated CYP2D6 alleles only explains 
a fraction (10%–30%) of the UM phenotype observed in Caucasian 
populations, and other biochemical and/or genetic factors involved 
in UM phenotype remain unexplained yet. CYP2D6 -1584C> G has 
been related with changes in CYP2D6 expression, being -1584G 
associated with higher expression. The aim of this study was to 
explore the relationship between CYP2D6 -1584C> G polymorphism 
and the debrisoquine hydroxylation capacity.
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Patients (or Materials) and Methods: Three hundred twenty unre-
lated healthy individuals from Cuba and Nicaragua were included 
to analyze the CYP2D6 -1584C> G polymorphism using PCR-RFLP. 
These subjects were also previously genotyped for CYP2D6 and phe-
notyped for debrisoquine hydroxylation.1
Results: Individuals with -1584G allele had a lower metabolic ratio 
(log10 mean [SD]) than individuals with -1584C allele among carri-
ers of one (–0.13 [0.33] and 0.17 [0.52], respectively; P < 0.05) or 
2 (–0.32 [0.39] and –0.20 [0.44], respectively; P < 0.05) CYP2D6 
active genes. No differences were observed in individuals with > 2 
CYP2D6 active genes (–0.85 [0.69] and –0.59 [0.40], respectively).
Conclusion: CYP2D6 -1584C> G polymorphism was related with 
higher debrisoquine hydroxylation capacity in individuals with 1 or 
2 CYP2D6 active genes.
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Introduction: Epilepsy is treated with a variety of anticonvulsants 
including lamotrigine (LTG). Patients treated with antiepileptic drugs 
can exhibit large interindividual variability in clinical efficacy and 
adverse effects. LTG is widespread used for the treatment of partial 
and generalized epilepsy seizures. It is mainly metabolized by the 
phase II enzyme UGT1A4 (UDP-glucuronosyl transferase 1A4) to 
2-N-glucuronide. Functional studies of the 2 nonsynonymous genetic 
polymorphisms UGT1A4*2 (P24T) and UGT1A4*3b (L48V) have 
shown decreased enzyme activity on various substrates, including 
LTG.
Aims: To investigate the impact of UGT1A4*1b, UGT1A4*2 and 
UGT1A4*3b polymorphism on LTG plasma levels and clinical 
response in epileptic patients.
Patients (or Materials) and Methods: Forty-nine patients with epi-
lepsy (17–67 years old) treated with LTG gave informed consent 
to participate in the study. Nine patients were under monotherapy. 
Genomic DNA was extracted from peripheral blood samples by 
standard technique. Genotyping was performed by real-time PCR 
using allele-specific probes. LTG plasma levels were determined by 
HPLC analysis. Clinical response was evaluated by seizures control 
(responder, 0–1 seizure/month).
Results: The results of the present study showed a great interindi-
vidual variability in plasma levels between 1.1 and 22.3 µg/mL, even 
among patients under the same posology. The UGT1A4 genotype 
showed a tendency to modify the LTG plasma level, although no 
statistically difference was achieved (P = 0.1175). It was also found 
that .43% of the patients responded to treatment. Among mono-
therapy cases, the patient with the highest LTG plasma level (9.5 µg/
mL) exhibited UGT1A4 wt/*3b genotype.
Conclusion: Our results indicate that UGT1A4*1b, *2 y *3b poly-
morphism did not have an important impact in the clinical response 
to LTG in the 49 epileptic patients studied. Nevertheless, further 
investigations are needed with a larger sample.
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